The U.S. healthcare system, including patients, employers and taxpayers, saved $408 billion in 2022 by using FDA-approved generic and biosimilar drugs, per the AAM's report.
The proposed settlement, which needs court approval, will provide consumers who participated in the lawsuit with “approximately double their out-of-pocket damages,” according to reports.
Lisdexamfetamine dimesylate is indicated for the treatment of ADHD in patients 6 years and above and for adults with moderate to severe Binge Eating Disorder.